Arcturus Therapeutics (ARCT) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free ARCT Stock Alerts $29.78 -0.72 (-2.36%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 11:50 AM | marketbeat.com207,127 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by Great Lakes Advisors LLCGreat Lakes Advisors LLC acquired a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 207,127 shares of the bioMay 18 at 2:53 AM | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Growth in Short InterestMay 17 at 9:00 PM | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. lessened its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 4.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,320,652 shares oMay 17 at 10:09 AM | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics Amidst Promising Gene Therapy AdvancesMay 16, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 5.9%Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 5.9%May 16, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest UpdateArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,920,000 shares, an increase of 6.7% from the April 15th total of 4,610,000 shares. Based on an average daily volume of 506,100 shares, the short-interest ratio is presently 9.7 days. Currently, 20.0% of the shares of the stock are sold short.May 15, 2024 | businesswire.comArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesMay 14, 2024 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of "Buy" from BrokeragesMay 12, 2024 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards GrowthMay 12, 2024 | americanbankingnews.comCanaccord Genuity Group Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $86.00May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical AdvancementsMay 10, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) PT Lowered to $86.00 at Canaccord Genuity GroupCanaccord Genuity Group reduced their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a "buy" rating for the company in a research note on Friday.May 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $27.21Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $27.21May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights:May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | investorplace.comARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comArcturus Therapeutics: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressMay 2, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.1%Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 6.1%May 1, 2024 | marketbeat.comArcturus Therapeutics (ARCT) Scheduled to Post Earnings on WednesdayArcturus Therapeutics (NASDAQ:ARCT) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589903)April 29, 2024 | finance.yahoo.comArcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five yearsApril 25, 2024 | businesswire.comArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024April 23, 2024 | seekingalpha.comArcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic FibrosisApril 20, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.Sumitomo Mitsui Trust Holdings Inc. trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 4.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor oApril 17, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Down 3.2%Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 3.2%April 16, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Up 3.4%Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 3.4%April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)April 14, 2024 | marketbeat.comShort Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Rises By 14.3%Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,810,000 shares, a growth of 14.3% from the March 15th total of 4,210,000 shares. Based on an average trading volume of 454,500 shares, the short-interest ratio is currently 10.6 days. Currently, 19.6% of the shares of the stock are short sold.April 11, 2024 | marketbeat.comVanguard Group Inc. Sells 221,573 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Vanguard Group Inc. trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 13.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,406,843 shares of the biotechnology compApril 9, 2024 | markets.businessinsider.comAlnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic PartnershipsApril 6, 2024 | cnn.comArcturus Therapeutics Holdings, Inc.April 4, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.3% Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.3%April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline ProgressMarch 31, 2024 | marketbeat.comSG Americas Securities LLC Trims Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)SG Americas Securities LLC cut its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 56.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,278 shares of the bMarch 29, 2024 | finanznachrichten.deIntravacc B.V.: Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine DevelopmentMarch 28, 2024 | insidertrades.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $610,573.70 in StockMarch 28, 2024 | marketbeat.comARK Investment Management LLC Acquires 146,141 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)ARK Investment Management LLC boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,047,687 shares of the biotechnologyMarch 28, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) Insider Sells SharesMarch 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in JapanMarch 26, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.5%Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.5%March 22, 2024 | insidertrades.comInsider Selling: Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells 8,565 Shares of StockMarch 22, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...March 21, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $299,860.65 in StockArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) COO Pad Chivukula sold 8,565 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.01, for a total transaction of $299,860.65. Following the transaction, the chief operating officer now owns 490,883 shares of the company's stock, valued at $17,185,813.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 20, 2024 | marketbeat.comArcturus Therapeutics' (ARCT) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday.March 19, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Up 3%Arcturus Therapeutics (NASDAQ:ARCT) Trading 3% HigherMarch 18, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.3%Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.3%March 18, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 6.6% in FebruaryArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 29th, there was short interest totalling 4,220,000 shares, a decrease of 6.6% from the February 14th total of 4,520,000 shares. Based on an average trading volume of 419,100 shares, the days-to-cover ratio is currently 10.1 days. Approximately 17.3% of the shares of the company are sold short. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. ARCT Media Mentions By Week ARCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.670.42▲Average Medical News Sentiment ARCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼93▲ARCT Articles Average Week Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evolus News Longboard Pharmaceuticals News ALX Oncology News Tango Therapeutics News Disc Medicine News Praxis Precision Medicines News Dianthus Therapeutics News Zentalis Pharmaceuticals News Pliant Therapeutics News PureTech Health News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
